FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

مكتبة الأكواد

Female GH Optimization

GH Optimizationintermediate

85

التعاون

85
Share
البروتيدات

2

متوسط الجرعة اليومية (mcg)

2,200

المستوى

intermediate

تمت الإضافة

May 17, 2026

نظرة عامة

The Female GH Optimization stack pairs Ipamorelin with Tesamorelin specifically because these two peptides offer the most favorable side-effect profile for women seeking growth hormone benefits without androgenic or metabolic complications. Tesamorelin is a 44-amino-acid GHRH analog that is the only peptide in this category with full FDA approval (marketed as Egrifta for HIV-associated lipodystrophy). It stimulates pituitary GH production through the GHRH receptor, producing physiological GH pulses that closely mimic natural secretion patterns. Women naturally produce more GH than men (approximately 2x the daily output) but experience a sharper decline with age, making GH optimization particularly impactful for female physiology. Tesamorelin has been shown in clinical trials to reduce visceral adipose tissue by 15-20% without affecting subcutaneous fat — making it uniquely suited for the central adiposity pattern common in perimenopause and menopause. Its effects on IGF-1 are modest and predictable, staying within physiological ranges. Ipamorelin complements Tesamorelin by adding ghrelin-pathway stimulation without the appetite increase, cortisol elevation, or prolactin changes seen with other GH secretagogues. For women, the absence of prolactin effects is particularly important as elevated prolactin can disrupt menstrual cycles and breast tissue. The combination produces amplified GH pulses (via GHRH + GHS synergy) while maintaining clean hormonal profiles. Benefits typically observed include improved skin elasticity and thickness, reduced visceral fat, better sleep architecture, improved bone mineral density markers, and enhanced recovery from exercise. This stack is well-suited for women over 35 seeking comprehensive anti-aging and body composition benefits.

بروتوكول الجرعة

Ipamorelin

Every day· subcutaneous

قراءة المزيد عن Ipamorelin →

200 mcg

كل جرعة

Tesamorelin

Every day· subcutaneous

قراءة المزيد عن Tesamorelin →

2,000 mcg

كل جرعة

الأهداف والدليل

Growth hormoneBody compositionSkin qualitySleepBone density
درجة الدليل:تجربة عشوائية مزدوجة المراقبة البشرية

تحذيرات

  • Tesamorelin is FDA-approved (Egrifta) for HIV lipodystrophy. Off-label use for anti-aging is common but not approved. Ipamorelin remains FDA Category 2 (restricted) as of July 2026.

Comments

Sign in to join the discussion

تحذير: هذا الكود مقدم من قبل المجتمع ويهدف لغرض البحث فقط. لا يتحقق Peptide Contacts من سلامة أو فعالية الأكواد المقدمة. استشر محترف صحي مؤهل قبل استخدام أي بروتوكول بروتيني.